Amber, a transpersonal psychotherapist, discusses the healing potential of non-ordinary states of consciousness.
Similar Posts
MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀
In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥
MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.
MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.
Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMedStock #MindMed #MMED #MMEDF
Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
Interview with Joe Moore, Founder & CEO of Psychedelics Today
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
BIPOC Medicine Healing with the Ancestor Project
Charlotte James and “Dre” Wright of The Ancestor Project chat with our Director of Content, Jill Ettinger.
Could Psilocybin End Our Addiction Crisis?
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.